A recent study has found that low-income subsidies under the Medicare Part D program can help improve rates of persistence and adherence to breast cancer therapies among Hispanic and black women.
A recent study has found that low-income subsidies under the Medicare Part D program can help improve rates of persistence and adherence to breast cancer therapies among Hispanic and black women.
Prior studies have indicated that nonadherence and nonpersistence are higher in black and lower-income women receiving hormonal therapy for breast cancer. A group of researchers hypothesized that the high cost of therapy may be a significant factor impeding the continuation of treatment, and conducted a study to assess the impact of financial subsidies provided under Medicare Part D on racial and ethnic disparities in adherence and persistence. The findings were published in the Journal of Clinical Oncology.
Medicare Part D provides pharmaceutical coverage, but beneficiaries are responsible for premiums, deductibles, copays, and costs within a coverage gap. However, its Low-Income Subsidy program provides either partial or full subsidies for patients who cannot afford these additional costs, which could potentially lower rates of nonpersistence and nonadherence.
Using a Medicare claims database, the researchers identified 25,511 patients who had received hormonal therapy for breast cancer and classified them by race/ethnicity and subsidy status. They also calculated the rates of nonpersistence, defined as 90 consecutive days without a claim for a hormonal therapy prescription, and nonadherence, defined as a medication possession rate of less than 80%.
They found that 27% of the study cohort, but 77% of the Hispanic women and 70% of the black women, received the low-income subsidy. Hispanic and black women were more likely to continue treatment throughout the study period—69% of black patients and 70% of Hispanic patients were persistent after 2 years, compared with 61% of white patients.
Regardless of race or ethnicity, women receiving subsidies had higher rates of persistence than the women who did not, who “were 60% to 200% more likely to discontinue hormonal therapy in the first 35 months compared with the Low-Income Subsidy recipients of the same race or ethnicity,” according to the authors. Disparities were evident among women on unsubsidized healthcare; the time it took for one-quarter to discontinue therapy was 12 months for white women, 10 months for Hispanic women, and 9 months for black women.
While rates of adherence were similar among white, Hispanic, and black women, the researchers again observed significant disparities between the subsidized and unsubsidized groups of patients. Women receiving subsidies were 30% more likely to be adherent than those who did not get the subsidies, and the probability of adherence was 2.7% lower for unsubsidized women while they were in the Medicare coverage gap.
These results, according to the authors, point to the importance of subsidies as a tool for increasing adherence and persistence and thus improving cancer outcomes for minority and low-income women. In a novel finding, the subsidies eliminated or even reversed the racial and ethnic disparities in persistence observed among unsubsidized women.
The authors concluded that more policy efforts like the subsidies are needed to expand access and “improve equity in cancer outcomes.”
“Given the high costs of oral oncologic and supportive medications, the impact on disparities of other initiatives to reduce out-of-pocket costs deserves urgent study,” they wrote.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Cancer Labels on Alcohol? Ireland, Where Pubs Still Rule, Will Have Them by Next Year
March 17th 2025As St. Patrick's Day brings global celebrations involving alcohol, Ireland looks forward to rethinking excess consumption with a new tool set to arrive next year: the world's most comprehensive alcohol warning label.
Read More